سعر ليبوليكس 200 مجم 20 كبسولة 2022

Lipolex 200 mg (Sigma, Egypt): fenofibrate 200 mg capsules, a fibrate lipid-lowering agent; pack of 20.

• Adjunct to diet: severe hypertriglyceridaemia with or without low HDL-C; mixed hyperlipidaemia when a statin is contraindicated or not tolerated; mixed hyperlipidaemia at high CV risk in addition to a statin when TG and HDL-C are not adequately controlled.Population: Adults (not recommended under 18 years)electronic medicines compendium (eMC)
• Adjunct to diet for reduction of LDL-C, total-C, triglycerides and Apo B in adults with primary hypercholesterolaemia or mixed dyslipidaemia (Fredrickson IIa/IIb); adjunct to diet for adults with hypertriglyceridaemia (Fredrickson IV and V).Population: AdultsDailyMed (U.S. National Library of Medicine)

• Most commonly digestive, gastric or intestinal disorders; common: GI signs and symptoms (abdominal pain, nausea, vomiting, diarrhoea, flatulence), transaminases increased; also reported: headache, thromboembolism, pancreatitis, cholelithiasis, cutaneous hypersensitivity, muscle disorders, blood creatinine/homocysteine increase.International label, equivalent formulation · electronic medicines compendium (eMC)

• Hepatic insufficiency (including biliary cirrhosis and unexplained persistent liver function abnormality); known gallbladder disease; severe renal insufficiency (eGFR < 30); chronic or acute pancreatitis (except acute pancreatitis due to severe hypertriglyceridaemia); known photoallergy or phototoxic reaction with fibrates or ketoprofen; hypersensitivity.International label, equivalent formulation · electronic medicines compendium (eMC)
• Hypersensitivity to fenofibrate; hepatic or severe renal dysfunction including primary biliary cirrhosis and unexplained persistent liver function abnormality; pre-existing gallbladder disease.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Monitor transaminases every 3 months during the first 12 months then periodically; discontinue if AST/ALT exceed 3 x ULN or hepatitis is confirmed; pancreatitis reported; muscle toxicity including rare rhabdomyolysis (risk increased by hypoalbuminaemia and previous renal insufficiency); treat secondary causes of hyperlipidaemia first.International label, equivalent formulation · electronic medicines compendium (eMC)
• Serious drug-induced liver injury (including liver transplantation and death) reported postmarketing; monitor ALT, AST and total bilirubin at baseline and periodically and discontinue if liver injury develops; cholelithiasis (discontinue if gallstones found); caution with oral anticoagulants.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Oral anticoagulantsEnhances anticoagulant effect and bleeding risk; reduce anticoagulant dose by about one-third at start and adjust according to INR.electronic medicines compendium (eMC)
• CiclosporinSevere reversible renal impairment reported; monitor renal function closely and stop fenofibrate if laboratory parameters alter severely.electronic medicines compendium (eMC)
• HMG-CoA reductase inhibitors or other fibratesIncreased risk of serious muscle toxicity; use with caution and monitor closely.electronic medicines compendium (eMC)

• No adequate human data; animal studies not teratogenic, embryotoxic at maternally toxic doses; use in pregnancy only after careful benefit/risk assessment.International label, equivalent formulation · electronic medicines compendium (eMC)
• Unknown whether excreted in human milk; a risk to the suckling child cannot be excluded; should not be used during breast-feeding.International label, equivalent formulation · electronic medicines compendium (eMC)

• Fenofibrate: Prodrug hydrolysed to fenofibric acid, which activates PPAR-alpha, increasing lipolysis and elimination of triglyceride-rich particles and reducing apoprotein C-III.